Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for production animal practice, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Critical care (London, England) in 2026 evaluated soluble triggering receptor expressed on myeloid cells-1 as a predictive biomarker in sepsis: insights into cut-offs, mortality risk, and treatment guidance-secondary analysis of the Next GeneSiS-Trial..
Key Findings
Triggering receptor expressed on myeloid cells-1 (TREM-1) is one of the more recently described biomarkers for sepsis and currently of great interest, as an inhibitor called nangibotide (Inotrem, Paris, France) for TREM-1 has made it into a phase 3 study for the treatment of sepsis. TREM-1, as a pattern recognition receptor (PRRs), plays a crucial role in the immune defense of the host. Several studies revealed promising results for soluble TREM-1 (sTREM-1) as a biomarker for outcome prediction. However, its usefulness in different subgroups of sepsis and the cut-off threshold at which patients are exposed to a higher risk of mortality have...
Why It Matters for Veterinary Professionals
For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for production animal practice.
Practical Interpretation
The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.
Clinical Takeaway
Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.
Read the full article here.
List
Add
Please enter a comment